Longitudinal Changes in Cognitive Function in a Nationwide Cohort Study of Patients With Lymphoma Treated With Chemotherapy
Michelle C. Janelsins(University of Rochester), Charles E. Heckler(University of Rochester Medicine), Mostafa Mohamed(University of Rochester), Lori M. Minasian(National Cancer Institute), Supriya G. Mohile(University of Rochester Medical Center), Elizabeth Belcher(University of Rochester Medicine), Charles Kamen(University of Rochester), Gary R. Morrow(University of Rochester Medical Center), Jodi Geer(Metro-Minnesota Community Oncology Research Consortium), Shaker R. Dakhil(Cancer Center of Kansas), Allison Magnuson(University of Rochester Medical Center), Patrick M. Reagan(University of Rochester), Tim A. Ahles(Memorial Sloan Kettering Cancer Center), Marianne Melnik(Michigan Cancer Research Consortium), Luke J. Peppone(University of Rochester Medical Center)
Cited by 37
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k